Aliases & Classifications for Meniere Disease

MalaCards integrated aliases for Meniere Disease:

Name: Meniere Disease 56 12 52 25 36 43 39 17 71
Meniere's Disease 12 52 25 42 15
Ménière's Disease 74 52 25 6
Otogenic Vertigo 12 25
Ménière Disease 25 32
Primary Endolymphatic Hydrops 25
Meniere's Syndrome 25
Ménière's Vertigo 25
Auditory Vertigo 25
Menieres Disease 54
Mnire's Vertigo 12
Vertigo, Aural 71
Aural Vertigo 25



incomplete penetrance
onset usually between 30 and 50 years of age
prevalence of 0.5 to 1 in 1,000

autosomal dominant


meniere disease:
Inheritance autosomal dominant inheritance
Onset and clinical course incomplete penetrance


MalaCards categories:
Global: Rare diseases
Anatomical: Ear diseases

External Ids:

Disease Ontology 12 DOID:9849
OMIM 56 156000
KEGG 36 H01495
ICD9CM 34 386.0
MeSH 43 D008575
SNOMED-CT 67 13445001
ICD10 32 H81.0
MedGen 41 C0025281
UMLS 71 C0025281 C1527320

Summaries for Meniere Disease

Genetics Home Reference : 25 Ménière disease is a disorder of the inner ear that affects balance and hearing. This condition is characterized by sudden episodes of extreme dizziness (vertigo), a roaring sound in the ears (tinnitus), a feeling of pressure or fullness in the ears, and fluctuations in hearing. Episodes are often associated with nausea and vomiting, and they can severely disrupt activities of daily living. The episodes associated with Ménière disease generally last several hours. Studies suggest that episodes can be triggered by stress, tiredness (fatigue), emotional upset, illness, and dietary factors. The timing of these episodes is unpredictable; affected individuals may experience a cluster of episodes within a short period, followed by months or years without any symptoms. Ménière disease usually appears in adulthood, most often in a person's 40s or 50s. It is much less common in children and young adults. The symptoms of the disorder typically begin in one ear, although they may later involve both ears. Some people with Ménière disease have no symptoms of the disorder between episodes, particularly in the early stages of the disease. Over time, however, many affected individuals develop ongoing problems with unsteadiness, tinnitus, and a feeling of fullness in the ears. Additionally, permanent hearing loss eventually develops in many people with this disorder.

MalaCards based summary : Meniere Disease, also known as meniere's disease, is related to inner ear disease and neuroma, and has symptoms including vertigo, tinnitus and snoring. An important gene associated with Meniere Disease is FAM136A (Family With Sequence Similarity 136 Member A), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. The drugs Sodium citrate and Betahistine have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and brain, and related phenotypes are hearing impairment and vertigo

Disease Ontology : 12 A vestibular disease characterized by vertigo, low-pitched tinnitus and hearing loss.

NIH Rare Diseases : 52 Meniere's disease is an abnormality of the inner ear. Signs and symptoms may include disabling vertigo or severe dizziness lasting from minutes to hours; tinnitus or a roaring sound in the ears; fluctuating hearing loss ; and the sensation of pressure or pain in the affected ear. A small percentage of people have drop attacks . The disorder usually affects only one ear, but some people develop symptoms in both ears many years after their initial diagnosis. Although the exact cause of Meniere's disease is unknown, the symptoms are thought to be associated with a change in fluid volume within a portion of the inner ear known as the labyrinth. Treatment may include medications or surgery depending on the severity of the condition.

OMIM : 56 Meniere disease is a chronic illness characterized by intermittent episodes of vertigo lasting from minutes to hours, with fluctuating sensorineural hearing loss, tinnitus, and aural pressure (Sajjadi and Paparella, 2008). (156000)

MedlinePlus : 42 Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss. Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have "drop attacks" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders

KEGG : 36 Meniere disease is an inner ear disorder characterized by episodic vertigo attacks, sensorineural hearing loss, tinnitus, and aural fullness. Prevailing theories on its pathogenesis point to endolymphatic hydrops as one derangement responsible for producing dysfunction within the cochlea and peripheral vestibular apparatus. Although the familial clustering and the geographical and racial differences in incidence suggest a certain role for genetic factors in the development of Meniere disease, no convincing evidence for an association with any gene exists, at present.

Wikipedia : 74 Ménière's disease (MD) is a disorder of the inner ear that is characterized by episodes of feeling like... more...

Related Diseases for Meniere Disease

Diseases related to Meniere Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
# Related Disease Score Top Affiliating Genes
1 inner ear disease 31.1 MIP COCH AQP6 AQP1
2 neuroma 30.9 AQP6 AQP4 AQP1
3 vestibular disease 30.6 FAM136A DTNA COCH AQP2
4 deafness, autosomal dominant 9 30.6 FAM136A COCH
5 acoustic neuroma 30.5 AQP6 AQP4 AQP1
6 deafness, autosomal dominant 15 30.4 FAM136A COCH
7 peripheral vertigo 30.4 FAM136A DTNA COCH AQP6 AQP2 AQP1
8 intraocular pressure quantitative trait locus 29.9 PTGFR MIP COCH AQP4 AQP1
9 alopecia areata 29.9 PTPN22 MIF HLA-DRB1
10 bone inflammation disease 29.7 TLR10 PTPN22 HLA-DRB1
11 active cochleovestibular meniere's disease 11.3
12 active vestibular meniere's disease 11.3
13 active cochlear meniere's disease 11.3
14 kanzaki disease 11.3
15 branchiootic syndrome 1 10.6
16 subependymoma 10.5 AQP4 AQP1
17 otosclerosis 10.4
18 autoimmune optic neuritis 10.4 MIP AQP4
19 migraine with or without aura 1 10.4
20 sensorineural hearing loss 10.4
21 idiopathic edema 10.4 AQP2 AQP1
22 deafness, autosomal dominant 28 10.4 FAM136A COCH
23 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
24 acrokeratoderma, hereditary papulotranslucent 10.4 AQP5 AQP3
25 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.4
26 central pontine myelinolysis 10.4 AQP4 AQP2 AQP1
27 dysferlinopathy 10.3 MIP AQP4 AQP1
28 facial paralysis 10.3
29 syphilis 10.3
30 pathologic nystagmus 10.3
31 auditory system disease 10.3
32 hydrops, lactic acidosis, and sideroblastic anemia 10.3 MIP AQP4
33 labyrinthitis 10.3
34 sleep apnea 10.2
35 syncope 10.2
36 oligohydramnios 10.2 AQP7 AQP3 AQP1
37 inappropriate adh syndrome 10.2 AQP4 AQP3 AQP2 AQP1
38 ataxia and polyneuropathy, adult-onset 10.2
39 autoimmune inner ear disease 10.2
40 head injury 10.2
41 headache 10.2
42 palindromic rheumatism 10.2 PTPN22 HLA-DRB1
43 hearing loss, noise-induced 10.2
44 bullous keratopathy 10.2 MIP AQP4 AQP3 AQP1
45 brain edema 10.2 MIP AQP5 AQP4 AQP1
46 benign paroxysmal positional nystagmus 10.2
47 rheumatoid vasculitis 10.2 MIF HLA-DRB1
48 hypothyroidism 10.1
49 herpes simplex 10.1
50 age-related hearing loss 10.1

Comorbidity relations with Meniere Disease via Phenotypic Disease Network (PDN):

Active Vestibular Meniere's Disease Anxiety
Esophagitis Hypertension, Essential
Hypothyroidism Labyrinthitis
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Meniere Disease:

Diseases related to Meniere Disease

Symptoms & Phenotypes for Meniere Disease

Human phenotypes related to Meniere Disease:

# Description HPO Frequency HPO Source Accession
1 hearing impairment 31 HP:0000365
2 vertigo 31 HP:0002321
3 tinnitus 31 HP:0000360

Symptoms via clinical synopsis from OMIM:

Head And Neck Ears:
vertigo, episodic
hearing impairment, sensorineural, fluctuating
aural fullness

Clinical features from OMIM:


UMLS symptoms related to Meniere Disease:

vertigo, tinnitus, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Meniere Disease according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.5 PRKCB
2 Decreased viability GR00221-A-2 9.5 PRKCB
3 Decreased viability GR00221-A-4 9.5 PRKCB
4 Decreased viability GR00249-S 9.5 DTNA MIP PRKCB
5 Decreased viability GR00381-A-1 9.5 AQP1 DTNA
6 Decreased viability GR00381-A-3 9.5 DTNA
7 Decreased viability GR00386-A-1 9.5 HLA-DRB1 SLC44A2
8 Decreased viability GR00402-S-2 9.5 AQP1 AQP5 PRKCB PTGFR

MGI Mouse Phenotypes related to Meniere Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 hearing/vestibular/ear MP:0005377 9.5 AQP1 AQP3 AQP4 AQP5 COCH MIF
2 renal/urinary system MP:0005367 9.17 AQP1 AQP2 AQP3 AQP4 AQP6 AQP7

Drugs & Therapeutics for Meniere Disease

Drugs for Meniere Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Sodium citrate Approved, Investigational Phase 4 68-04-2
Betahistine Approved, Investigational Phase 4 5638-76-6 2366
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
13 Tocotrienol Investigational Phase 4 6829-55-6
14 Protective Agents Phase 4
15 Phosphodiesterase 5 Inhibitors Phase 4
16 Phosphodiesterase Inhibitors Phase 4
17 Citrate Phase 4
18 Vasodilator Agents Phase 4
19 Sildenafil Citrate Phase 4 171599-83-0
20 Pharmaceutical Solutions Phase 4
21 Micronutrients Phase 4
22 Trace Elements Phase 4
23 Vitamins Phase 4
24 Vitamin B Complex Phase 4
25 Antioxidants Phase 4
26 Vitamin B3 Phase 4
27 Nicotinic Acids Phase 4
28 Lipid Regulating Agents Phase 4
29 Nutrients Phase 4
30 Folate Phase 4
31 Tocotrienols Phase 4
32 Tocopherols Phase 4
33 Vitamin B9 Phase 4
34 Hypolipidemic Agents Phase 4
35 Antimetabolites Phase 4
protease inhibitors Phase 4
37 HIV Protease Inhibitors Phase 4
38 Dexamethasone 21-phosphate Phase 4
39 BB 1101 Phase 4
40 Anesthetics Phase 4
41 Hormones Phase 4
42 Gastrointestinal Agents Phase 4
43 Antineoplastic Agents, Hormonal Phase 4
44 Antiemetics Phase 4
45 Hormone Antagonists Phase 4
46 Anti-Bacterial Agents Phase 4
47 Anti-Infective Agents Phase 4
48 glucocorticoids Phase 4
49 Anti-Inflammatory Agents Phase 4
50 Opiate Alkaloids Phase 4

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Of The Efficacy and Safety Of Sildenafil Given For The Acute Treatment Of Meniere's Disease Completed NCT00145483 Phase 4 Sildenafil
2 A Double-Blind, Placebo-Controlled, Randomized, Clinical Study of the Effects of Betaserc® 24 mg (1 Tablet b.i.d Over 3 Months) on Vestibular Compensation Following Vestibular Neurotomy in Patients With Disabling Menière's Disease Completed NCT00160238 Phase 4 Betahistine 24 mg bid (Betaserc)
3 Phase 3 Study of Efficacy of Local Overpressure Treatment for Meniere's Disease Completed NCT00831688 Phase 4
4 A Multicenter, Randomized, Open-label Clinical Study With a Concurrent Control Group to Assess the Effectiveness and Safety of Combined Therapy With Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets for Patients With Meniere's Disease Completed NCT02718846 Phase 4 Meniace;Isobide
5 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
6 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment. Completed NCT01372904 Phase 4 Dexamethasone Phosphate
7 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS) Recruiting NCT02529475 Phase 4 Gadoteric acid
8 Effect of Adding Azithromycin to Dexamethasone in Preventing Post-operative Nausea and Vomiting in Caesarean Section Under Spinal Anesthesia With Spinal Opiate. Not yet recruiting NCT03165123 Phase 4 Oral Azithromycin tablet;Intravenous dexamethasone
9 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease Suspended NCT02530931 Phase 4 Gadolinium
10 Assessment of Acyclovir Efficacy Versus Placebo in Controlling Vertigo Attacks of Patients With Meniere's Disease Visited in Amiralam Hospital Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
11 Antisecretory Factor (AF) Effects on Intraocular-pressure: a Placebo-controlled Randomised Study Unknown status NCT02731118 Phase 3
12 Lamotrigine for Ménière's Disease: a Double-blind, Placebo-controlled Pilot Study Completed NCT02158585 Phase 3 Lamotrigine;Placebo
13 Effectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial Completed NCT00802529 Phase 2, Phase 3 Methylprednisolone;Gentamicin
14 A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease Completed NCT02612337 Phase 3 OTO-104;Placebo
15 A Random Controlled Clinical Trial:l Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease Completed NCT01454726 Phase 3
16 Conventional Versus Virtual Reality Based Vestibular Rehabilitation; Effect on Dizziness, Gait and Balance Completed NCT01442623 Phase 2, Phase 3
17 A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease Recruiting NCT03664674 Phase 3 OTO-104;Placebo
18 Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes Recruiting NCT04218123 Phase 2, Phase 3 Venlafaxine;Placebo oral tablet
19 Salovum (Antisecretory Factor) in Patients With Severe Traumatic Brain Injury Recruiting NCT03339505 Phase 3
20 A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease Terminated NCT02717442 Phase 3 OTO-104;Placebo
21 A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease Terminated NCT02768662 Phase 3 OTO-104
22 A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease Terminated NCT02706730 Phase 3 OTO-104
23 Treatment of Hearing Fluctuation in Unilateral Meniere's Disease: A Randomized, Placebo-controlled Clinical Trial of Famciclovir Terminated NCT01526408 Phase 3 Famciclovir;Placebo
24 A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Menière's Disease Unknown status NCT01973114 Phase 2 Latanoprost
25 A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2b Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease Completed NCT01412177 Phase 2 OTO-104;Placebo
26 A 6-Month, Prospective, Randomized, Multicenter, Placebo-Controlled Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease Followed by a 6-Month Open-Label Extension Completed NCT02265393 Phase 2 OTO-104;Placebo
27 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease Completed NCT03325790 Phase 2 200mg SPI-1005 BID;400mg SPI-1005 BID
28 Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease Completed NCT02603081 Phase 1, Phase 2 SPI-1005
29 An Open-label Study of the Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2 gevokizumab
30 A Phase I/II Open-label Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2 Anakinra
31 The Attenuation of Second Generation Antipsychotic Induced Weight Gain in Adolescents and Adults Using Betahistine: A Double-Blind, Placebo-Controlled Trial Completed NCT00709202 Phase 2 Betahistine;Placebo Oral Tablet
32 A Phase II Placebo Controlled Study of the Effects of Anakinra (Kineret) in Subjects With Corticosteroid-Resistant Meniere's Disease (CR-MD) and Corticosteroid-Resistant Autoimmune Inner Ear Disease Disease (CR-AIED) Recruiting NCT03587701 Phase 2 Anakinra 100Mg/0.67Ml Inj Syringe (Period 1);Placebo injection (Period 1);Anakinra 100Mg/0.67Ml Inj Syringe (Period 2);Placebo injection (Period 2)
33 A 1-Year, Phase 2, Open-Label Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease Terminated NCT02740387 Phase 2 OTO-104
34 A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 1B Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease Completed NCT01084525 Phase 1 OTO-104 (steroid) 3 mg;Placebo;OTO-104 (steroid) 12 mg
35 Diagnostic Agreement of Electrophysiological Audiovestibular Examinations With Magnetic Resonance Imaging (MRI) of the Inner Ear in Revealing Endolymphatic Hydrops (EH) in Patients With Certain or Probable Meniere's Disease (MD) Unknown status NCT03215420
36 Reduction of Plasma Vasopressin Level in Patients With Meniere's Disease Unknown status NCT01099046
37 Consequence of Unilateral Vestibular Loss on Visual Abilities Unknown status NCT03581331
38 Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI Unknown status NCT03593577
40 Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent Completed NCT02080312 Magnevist (gadopentetate dimeglumine)
41 Vasopressin and V2 Receptor in Meniere's Disease Completed NCT00599560
42 Clinical Study of Endolymphatic Sac Drainage With or Without Steroids for Intractable Meniere's Disease Completed NCT00500474
43 Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach Completed NCT02309099
44 Post-marketing Observational Program of Betaserc® (Betahistine Dihydrochloride) to Evaluate Effectiveness in Patients With Vestibular Vertigo in Routine Practice Completed NCT01759251
45 Effect of Preoperative Oral Carbohydrate Loading on Recovery in Patients Undergoing Day-case Cholecystectomy. A Randomised Controlled Trial. Completed NCT03757208
46 Effects of Kinesio Taping in Patients With Somatosensory Tinnitus: A Randomized Controlled Trial Completed NCT03782220
47 A Randomized Trial to Evaluate Resolution of Symptoms Using Vestibular Rehab Versus Conventional Therapy in Patients Presenting to the Emergency Department (ED) With Diagnosis of Benign Paroxysmal Positional Vertigo (BPPV) Completed NCT00641797 Meclizine;Lorazepam;Diphenhydramine;Ondansetron
48 Cochlear Implantation During Vestibular Schwannoma Removal or During Labyrinthectomy Surgery for Treatment of Meniere's Disease Recruiting NCT03795675
49 Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Dizziness Trial Recruiting NCT04026516
50 Transcranial Vibrating System for Improving Outcomes of Vestibular Physical Therapy Recruiting NCT03795168

Search NIH Clinical Center for Meniere Disease

Cochrane evidence based reviews: meniere disease

Genetic Tests for Meniere Disease

Anatomical Context for Meniere Disease

MalaCards organs/tissues related to Meniere Disease:

Testes, Bone, Brain, Eye, Cortex, Heart, Breast

Publications for Meniere Disease

Articles related to Meniere Disease:

(show top 50) (show all 2479)
# Title Authors PMID Year
Absence of COCH mutations in patients with Meniere disease. 56 54 61
14704763 2004
A novel missense variant in PRKCB segregates low-frequency hearing loss in an autosomal dominant family with Meniere's disease. 61 56
27329761 2016
Identification of two novel mutations in FAM136A and DTNA genes in autosomal-dominant familial Meniere's disease. 61 56
25305078 2015
Familial clustering and genetic heterogeneity in Meniere's disease. 61 56
23521103 2014
Meniere's disease. 56 61
18675691 2008
The cause (multifactorial inheritance) and pathogenesis (endolymphatic malabsorption) of Meniere's disease and its symptoms (mechanical and chemical). 61 56
4013733 1985
Anticipation in Menière's disease. 56
7642988 1995
Occurrence of episodic vertigo and hearing loss in families. 56
5892598 1965
Clinical Practice Guideline: Ménière's Disease. 42
32267799 2020
Magnetic resonance imaging of Ménière's disease: early clinical experience in a UK centre. 42
32241307 2020
Depression in Ménière's disease: a systematic review and meta-analysis. 42
32301406 2020
Aquaporins as potential drug targets for Meniere's disease and its related diseases. 61 54
19096777 2009
Aquaporins and Meniere's disease. 61 54
16974147 2006
Validity of the Western blot immunoassay for heat shock protein-70 in associated and isolated immunorelated inner ear disease. 54 61
11889388 2002
Anti-heat shock protein 70 antibodies in Meniere's disease. 54 61
11224793 2001
Proteomics and the inner ear. 61 54
11790893 2001
Anti-heat shock protein 70 antibodies in Meniere's disease. 61 54
10983953 2000
Recognition of a dominant epitope in bovine heat-shock protein 70 in inner ear disease. 61 54
10201752 1999
Failure of elevated heat shock protein 70 antibodies to alter cochlear function in mice. 61 54
9508029 1998
Comparison of anti-heat shock protein 70 (anti-hsp70) and anti-68-kDa inner ear protein in the sera of patients with Meniere's disease. 61 54
9023247 1997
The role of caloric testing and the vestibular evoked myogenic potential in the efficacy of intratympanic dexamethasone injection in 201 patients with unilateral Meniere's disease. 61
32304344 2020
Author's reply to the Letter to the Editor "Therapeutic strategies in the treatment of Menière's disease: the Italian experience". 61
32219526 2020
A Revised Surgical Approach to Induce Endolymphatic Hydrops in the Guinea Pig. 61
32568243 2020
Contralesional subjective visual horizontal predicts endolymphatic hydrops. 61
32552133 2020
Expression of aquaporins in inner ear disease. 61
31593306 2020
The pharmacological management of vertigo in Meniere disease. 61
32539493 2020
Current status on researches of Meniere's disease: a review. 61
32564698 2020
Dexamethasone protects the hearing of Meniere's disease patients after triple semicircular canal plugging. 61
32564634 2020
Letter to Editor concerning the "Therapeutic strategies in the treatment of Meniere's disease: the Italian Experience". 61
31912215 2020
Clinical features and outcomes of benign recurrent vertigo: A longitudinal study. 61
31883379 2020
A Micro-CT and Synchrotron Imaging Study of the Human Endolymphatic Duct with Special Reference to Endolymph Outflow and Meniere's Disease. 61
32427861 2020
Comparison of the video head impulse test results with caloric test in patients with Meniere's disease and other vestibular disorders. 61
32437211 2020
Tone burst electrocochleography disproves a diagnosis of Meniere's disease treated aggressively. 61
31428809 2020
Erratum to "'Algorithm' for Meniere's Disease" [Eur. Ann. Otorhinolaryngol. 1S (2018) S29-S32]. 61
32273186 2020
Prediction of Unilateral Meniere's Disease Attack Using Inner Ear Test Battery. 61
31567497 2020
In Reference to Chronic Cerebrospinal Venous Insufficiency and Meniere's Disease: Interventional Versus Medical Therapy. 61
32374415 2020
Dietary Restriction for The Treatment of Meniere's Disease. 61
32523900 2020
The natural progression of low-frequency hearing loss in patients who meet hybrid implant system candidacy criteria. 61
31393603 2020
Diagnostic value of refixation saccades in the Video Head Impulse Test (vHIT) in unilateral definite Meniere's disease. 61
32293917 2020
Change of VOR gain and pure-tone threshold after single low-dose intratympanic gentamicin injection in Meniere's disease. 61
31909683 2020
Dissociated Results between Caloric and Video Head Impulse Tests in Dizziness: Prevalence, Pattern, Lesion Location, and Etiology. 61
32319245 2020
Current Validated Medical Treatments: Pharmacologic Interventions. 61
32334873 2020
Impact of Underlying Diagnosis on Speech and Quality of Life Outcomes After Cochlear Implantation for Single-Sided Deafness. 61
32176127 2020
Bilateral posterior semicircular canal dysfunction: a new finding with video head impulse test. 61
32347336 2020
Etiologic distribution of dizziness and vertigo in a referral-based dizziness clinic in South Korea. 61
32300888 2020
[In vivo dynamic changes of inner ear guinea pigs with 9.4 T esla MRI]. 61
32306636 2020
Heritability and Genetics Contribution to Tinnitus. 61
32334875 2020
Experimental Animal Models for Meniere's Disease: A Mini-Review. 61
32248670 2020
Is Endolymphatic Sac Surgery Beneficial For Meniere's Disease? 61
32243594 2020
Therapeutic role of intravenous glycerol for Meniere's disease. Preliminary results. 61
32354483 2020

Variations for Meniere Disease

ClinVar genetic disease variations for Meniere Disease:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FAM136A NM_001329752.2(FAM136A):c.547C>T (p.Gln183Ter)SNV Pathogenic 140608 2:70527974-70527974 2:70300842-70300842
2 DTNA NM_001390.4(DTNA):c.2143G>T (p.Val715Phe)SNV Likely pathogenic 140609 18:32462094-32462094 18:34882130-34882130

Expression for Meniere Disease

Search GEO for disease gene expression data for Meniere Disease.

Pathways for Meniere Disease

Pathways related to Meniere Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
4 11.58 MIF AQP4 AQP1
5 11.08 AQP4 AQP3 AQP2

GO Terms for Meniere Disease

Cellular components related to Meniere Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.27 TLR10 SLC44A2 SEMA3D PTGFR PRKCB MIP
2 integral component of membrane GO:0016021 10 TLR10 SLC44A2 SEMA3D PTGFR MIP HRH4
3 plasma membrane GO:0005886 9.86 TLR10 SLC44A2 PTGFR PRKCB MIP MIF
4 basolateral plasma membrane GO:0016323 9.71 AQP4 AQP3 AQP2 AQP1
5 apical plasma membrane GO:0016324 9.65 MIP AQP6 AQP5 AQP2 AQP1
6 cytoplasmic vesicle membrane GO:0030659 9.62 AQP7 AQP6 AQP5 AQP2
7 sarcolemma GO:0042383 9.61 DTNA AQP4 AQP1
8 integral component of plasma membrane GO:0005887 9.4 TLR10 SEMA3D PTGFR MIP HRH4 HLA-DRB1

Biological processes related to Meniere Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.81 SLC44A2 MIP AQP7 AQP6 AQP5 AQP4
2 protein homotetramerization GO:0051289 9.71 MIP AQP5 AQP4 AQP2
3 odontogenesis GO:0042476 9.67 AQP6 AQP5 AQP3 AQP1
4 renal water homeostasis GO:0003091 9.62 AQP4 AQP3 AQP2 AQP1
5 multicellular organismal water homeostasis GO:0050891 9.52 AQP4 AQP1
6 urea transmembrane transport GO:0071918 9.51 AQP7 AQP3
7 cellular water homeostasis GO:0009992 9.49 AQP4 AQP1
8 pancreatic juice secretion GO:0030157 9.48 AQP5 AQP1
9 cellular response to mercury ion GO:0071288 9.46 AQP2 AQP1
10 renal water transport GO:0003097 9.43 AQP2 AQP1
11 carbon dioxide transport GO:0015670 9.43 AQP6 AQP5 AQP1
12 glycerol transport GO:0015793 9.26 AQP7 AQP3 AQP2 AQP1
13 water transport GO:0006833 9.23 MIP AQP7 AQP6 AQP5 AQP4 AQP3

Molecular functions related to Meniere Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 channel activity GO:0015267 9.56 MIP AQP7 AQP6 AQP5 AQP4 AQP3
2 urea transmembrane transporter activity GO:0015204 9.37 AQP7 AQP3
3 water transmembrane transporter activity GO:0005372 9.32 AQP2 AQP1
4 glycerol channel activity GO:0015254 9.26 AQP7 AQP3
5 water channel activity GO:0015250 9.23 MIP AQP7 AQP6 AQP5 AQP4 AQP3
6 glycerol transmembrane transporter activity GO:0015168 9.16 AQP2 AQP1

Sources for Meniere Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....